Press Releases

Press Releases

Dec 09, 2024

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 14, 2024

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 07, 2024

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Nov 05, 2024

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Aug 05, 2024

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

May 29, 2024

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 23, 2024

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

May 09, 2024

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

May 08, 2024

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 08, 2024

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Apr 22, 2024

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 03, 2024

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Apr 01, 2024

CRISPR Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting

Mar 13, 2024

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Feb 21, 2024

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

Feb 13, 2024

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Feb 13, 2024

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Jan 16, 2024

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Jan 08, 2024

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

Jan 03, 2024

CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference